Update: the EU-US deal (effective July 1, 2026) caps EU branded pharma at 15% — Ireland and Germany are shielded from the threatened 100% rate. The onshoring deadline is July 31; agreements cut the tariff to 20%. Model your pharma import costs →
The threatened 100% tariff on patented branded drugs — the single highest product-specific rate in the current US trade book — now has a hard date attached: **July 31, 2026**, the deadline for major pharma companies to negotiate onshoring agreements. Sign one, and the tariff drops to 20%. Don't, and the threatened 100% applies. But the July 1 EU-US trade deal redrew the exposure map: **EU branded pharma is capped at 15% by the deal**, shielding Ireland (~$50B in US-bound branded drugs) and Germany (~$14B) from the 100% threat. Switzerland ($23B) is not an EU member and stays fully exposed. Generics remain outside the threat — and EU generics go MFN-only (typically 0%) on September 1. Here's what's actually in force, what's threatened, and how the July 31 deadline plays out country by country.
What's Actually In Force vs. Threatened (July 2026)
In force right now: EU-origin pharmaceuticals pay the trade deal's 15% all-inclusive ceiling (since July 1, 2026 — the ceiling applies in lieu of Section 232 for pharma); non-EU pharma imports pay 10% Section 122 until it expires July 24. MFN base on chapter 30 is 0% under the WTO Pharmaceutical Tariff Elimination Agreement. Threatened: a 100% tariff on branded pharmaceutical imports for companies that fail to negotiate onshoring agreements by July 31, 2026 — agreements reduce the rate to 20%. The exposure split has three tiers: EU branded pharma is capped at 15% by the deal regardless of the onshoring outcome; non-EU branded producers (Switzerland foremost) face 20% with an agreement or the threatened 100% without one; and off-patent generics stay outside the threat entirely, with EU generics going to MFN-only treatment (typically 0%) on September 1, 2026. The administration's stated rationale is reshoring — and the pressure track is widening: on June 18, 2026, USTR opened a Section 301 investigation against Germany over persistent underpayment for innovative pharmaceutical products.
Why Pharma Has Been Duty-Free Since 1995
The WTO Pharmaceutical Tariff Elimination Agreement of 1995 — signed by the US, EU, Japan, Switzerland, and others — eliminated MFN duty on roughly 7,000 pharmaceutical products in chapter 30. The Section 122 layer added 10% in February 2026 — the first US import duty on pharma in 30+ years. A 100% Section 232 layer on top would be the biggest reversal since the agreement was signed. The legal authority works because Section 232 supersedes the WTO commitment when invoked on national security grounds.
Advertisement
Worked Example: $1M Branded Drug Shipment from Ireland vs. Switzerland
A $1,000,000 CIF shipment of a patented branded drug from a Pfizer facility in Cork, Ireland, classified under HTS 3004.90 (other medicaments, retail-packaged). MFN: 0%. Since July 1, 2026, the EU deal's 15% ceiling governs: $150,000. MPF capped at $634.62 per entry, HMF at 0.125% = $1,250. Total duty: roughly $151,885 — effective rate about 15.2%, and capped there regardless of the July 31 onshoring outcome. Now run the identical $1M shipment from a Roche facility in Basel, Switzerland — not an EU member, not covered by the deal. Today: 10% Section 122 = $100,000. If the manufacturer signs an onshoring agreement by July 31: 20% = $200,000. If it doesn't and the threatened 100% lands: $1,000,000 of duty on a $1M shipment. The Ireland-vs-Switzerland delta under the worst case is roughly $850,000 per container on identical molecules — the deal turned EU origin into pharma's most valuable sourcing attribute.
Generics, APIs, and Medical Devices Stay Different
Generic drugs pay 10% Section 122 on top of 0% MFN — total 10%. The 100% rate is patent-specific. Active pharmaceutical ingredients (APIs, HTS 2941 and 2942) pay 10% Section 122 plus 0% MFN — same as generics. Medical devices (chapter 90) are excluded from chapter 30 and have their own MFN structure: most diagnostic equipment is 0%, surgical instruments 0%, dental equipment 0-2%. So the 100% threat does not hit Indian generic exporters (Cipla, Dr. Reddy's, Sun Pharma), it does not hit Chinese API producers (Section 301's separate 25% Chinese layer applies, putting Chinese APIs at 35% combined), and it does not hit medical device makers in Ireland or Germany. The 100% rate is a precision instrument aimed at branded patent-holding manufacturers — primarily US firms producing offshore to capture Irish and Swiss tax treatment.
Country Exposure: The EU Deal Redrew the Map
Ireland ships roughly $50B in pharma to the US annually, primarily branded patented drugs from Pfizer, Eli Lilly, AbbVie, Merck, and Johnson & Johnson facilities operating under Ireland's 12.5% corporate tax rate — and as of July 1, 2026, all of it is capped at 15% by the EU-US trade deal. Germany's ~$14B (Bayer, Boehringer Ingelheim) gets the same 15% cap, though Germany now faces a separate USTR Section 301 investigation (opened June 18, 2026) over underpayment for innovative drugs. Switzerland is the exposed one: ~$23B dominated by Roche and Novartis, not an EU member, not covered by the deal — Swiss branded pharma faces 20% with a July 31 onshoring agreement or the threatened 100% without one. India is the largest source of generic dose volume (~$9B, almost all generic) and stays outside the branded threat. China runs ~$2.5B mostly in APIs (35% effective with Section 301). The bottom line: the 100% threat is now effectively a Switzerland-and-everyone-else problem, not an Ireland problem.
The July 31 Onshoring Deadline
The mechanism is negotiation-forward: major pharmaceutical companies have until July 31, 2026 to negotiate onshoring agreements with the administration. Companies that sign commit to moving manufacturing to US soil in exchange for a 20% tariff rate; companies that don't face the threatened 100% on branded imports. Three carve-outs shape who actually has to negotiate: EU-origin branded pharma is capped at 15% by the trade deal regardless; EU generics, APIs, and chemical precursors go MFN-only (typically 0%) on September 1; and generics from any origin are outside the branded threat. Watch the days around July 31 — the deadline lands one week after the July 24 Section 122 expiry, in the same month USTR must complete its Section 301 investigations (July 20). For non-EU branded importers, assume an early-August effective date for whatever rate emerges.
What This Does to US Drug Prices
A 100% tariff flows into US patient prices — eventually. Drug companies pay duty at the port (the importer is usually the US sales sub of the multinational), and the duty becomes a cost of goods. On patented drugs with no generic competition, pricing power is high — 70-90% pass-through to commercial insurers and patient out-of-pocket over 12-24 months. Medicare Part D and Medicaid pricing is partly constrained by IRA negotiations, but rebates work off list price, and list prices reset upward to absorb the duty. US branded drug spending runs about $400B a year. The EU deal's 15% cap sharply reduces the worst case — roughly two-thirds of US-bound branded pharma value (Ireland, Germany, and other EU origins) is now capped at 15% rather than exposed to 100% — leaving the heaviest price pressure concentrated in Swiss-origin and other non-EU branded product that misses the July 31 onshoring deadline. The administration's counter is reshoring — but reshoring a major facility runs 5-7 years and tens of billions in capex. Duty hits 2026; reshoring offset arrives 2031 at the earliest.
What Importers Should Do This Week
Step 1: Sort every pharma SKU by origin — EU branded product is capped at 15% by the trade deal; only non-EU branded product (Switzerland foremost) carries July 31 risk. Step 2: For non-EU branded imports, model both post-deadline scenarios on Q3 2026 forecasts — 20% (onshoring agreement signed) and 100% (no agreement) — and consider back-loading inventory before an early-August effective date. Step 3: For EU generic and API lines, model the September 1 MFN-only shift — near-0% duty makes delaying non-urgent shipments worth real money. Step 4: For API buyers, Chinese APIs remain at 35% effective with Section 301 and carry separate escalation risk. Step 5: Confirm patent status on every imported SKU — a branded-vs-generic indicator will drive rate treatment on entries once the July 31 outcome lands. Step 6: Watch whether your manufacturers sign onshoring agreements — that single fact sets your rate at 20% versus 100% on non-EU branded lines.
Key Takeaway
Trump's pharma tariff structure now has three tiers, not two: EU branded pharma capped at 15% by the trade deal effective July 1, non-EU branded drugs facing 20% (with a July 31 onshoring agreement) or the threatened 100% (without one), and generics outside the threat — with EU generics going MFN-only on September 1. Ireland and Germany are shielded; Switzerland takes the hardest exposure; India's generics business stays insulated. The July 31 onshoring deadline lands a week after the Section 122 expiry, so pharma importers should treat late July as one continuous repricing event. Sort your SKUs by origin and patent status now, model 20%-vs-100% on every non-EU branded line, and watch which manufacturers sign onshoring agreements before the deadline.
Calculate Your Import Duty
Get an instant estimate for your specific product, country, and shipment value.
Open the US Import Duty CalculatorAdvertisement